Abstract 345P
Background
While induction with cytarabine containing immuno-chemotherapy is recommended for fit patients (pts) with newly diagnosed mantle cell lymphoma (MCL), the choice of accompanying platinum agent is less clear. Substitution to carboplatin simplifies chemotherapy administration and reduces nephrotoxicity. We aimed to assess the impact of up to 6 cycles of alternating RCHOP/RDHAC (carboplatin) as induction for transplant-eligible pts with MCL prior to BEAM autologous stem cell transplant (ASCT).
Methods
Single centre retrospective cohort study [2008-2023] of pts who commenced RCHOP/RDHAC for MCL. Descriptive statistics, Kaplan-Meier survival analysis, impact of baseline variables tested, and nephrotoxicity graded by CTCAE v5.
Results
Of 36 pts identified, 34 completed intended therapy. Median age was 63 yrs (range 37-76), 32 males (89%), stage 4=28 (78%), MIPI low 33%/int 47%/high 19%, aggressive morphology=19%, p53=90% (9/10) and high Ki67=63% (15/24). Mean induction relative dose intensity was 99% (SD 5%). Autograft was performed in 26 pts; insufficient stem cell collection in 1 patient. Response was evaluable by PET/CT prior to autograft in 31 pts; not assessed in 5 pts: 25 complete response, 5 partial response and 1 progressive disease (ORR 97%). By Jun 2023, with median (m) follow-up of 85 mo: 16 pts died, 12 relapsed; mPFS 90 mo and mOS 112 mo; mOS following relapse/progression 16 mo despite bruton tyrosine kinase inhibitor use in 7 pts (54%). Nephrotoxicity with induction was uncommon (Table); 1 pt required dialysis in setting of organ failure associated with sepsis. Median admission duration per pt for induction therapy was 5 days (IQR, 0-9.5). Table: 345P
Table: 345P Adverse events
No. pts | |
Creatinine increase- Grade 1/2- Grade 3/4 | 8 (22%)1 (3%) |
Acute kidney injuryˆ- Grade 3- Grade 4 | 1 (3%)1 (3%) |
Febrile neutropenia | 9 (25%) |
Transplant-related mortality* | 3 (8%) |
ˆincludes 1 pt with sepsis during stem cell mobilization with RDHAC; 1 pt with acute on chronic renal impairment with RCHOP*includes 1 pt with sepsis during stem cell mobilization with RDHAC
Conclusions
This retrospective analysis is one of the largest cohorts of RCHOP/RDHAC reported in MCL. Low rates of clinically relevant nephrotoxicity with comparable long-term outcomes highlight carboplatin substitution as an option in selected pts. Survival after relapse remains poor.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract